Background: There are no reliably effective therapies for alopecia areata (AA).
Objective: We sought to evaluate the benefit and adverse effects of the Janus kinase 1/3 inhibitor, tofacitinib, in a series of adolescent patients with AA.
Methods: We reviewed the records of 13 adolescent patients with AA treated with tofacitinib. Severity of disease was assessed using the Severity of Alopecia Tool (SALT). Adverse events were evaluated by laboratory monitoring, physical examinations, and review of systems.
Results: Thirteen patients, aged 12 to 17 years, with AA were treated with tofacitinib. Nine patients experienced clinically significant hair regrowth. Median percent change in SALT score was 93% (mean 61%; 1%-100%) at an average of 6.5 months of treatment. Adverse events were mild.
Limitations: Limitations include the retrospective nature of the data, small sample size, and lack of a control group.
Conclusion: Tofacitinib is a promising therapy for AA in adolescents. The use of tofacitinib and other Janus kinase inhibitors for the treatment of AA in this age group should be further evaluated in prospective clinical trials.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaad.2016.09.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pathogenesis of paradoxical alopecia areata during dupilumab therapy: What is known and unknown.
Int J Dermatol
January 2025
Department of Dermatology, University of British Columbia, Vancouver, British Columbia, Canada.
Differential Expression of CXCL12 in Human and Mouse Hair: Androgens Induce CXCL12 in Human Dermal Papilla and Dermal Sheath Cup.
Int J Mol Sci
December 2024
Epi Biotech Co., Ltd., Incheon 21983, Republic of Korea.
We previously demonstrated that C-X-C Motif Chemokine Ligand 12 (CXCL12) is primarily secreted by dermal fibroblasts in response to androgens and induces hair miniaturization in the mouse androgenic alopecia (AGA) model. However, the direct effects of androgen-induced CXCL12 on dermal papilla cells (DPCs) and dermal sheath cup cells (DSCs) have not been demonstrated. First, we compared single-cell RNA sequencing data between mouse and human skin, and the results show that CXCL12 is highly co-expressed with the androgen receptor (AR) in the DPCs and DSCs of only human hair.
View Article and Find Full Text PDFThe epidemiology of inflammatory skin disease in older adults.
JAAD Int
February 2025
Department of Dermatology, University of California, San Francisco, California.
Fractional CO Laser and Minoxidil in the Treatment of Alopecia Areata, A Comparative Study.
Lasers Surg Med
January 2025
Dermatology, Venereology and Andrology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Background: Alopecia areata (AA) is a chronic inflammatory disease that affects the hair follicles and sometimes the nails. It usually presents as a single or multiple patches of hair loss on the scalp, but any hair-bearing skin can be involved. AA treatment depends on the severity and extent of the disease.
View Article and Find Full Text PDFBirth Outcomes of Infants Born to Mothers with Alopecia Areata: A Nationwide Population-based Study in Korea.
Acta Derm Venereol
January 2025
Department of Preventive Medicine, Korea University College of Medicine, Seoul, Korea.
Data on pregnancy outcomes in patients with alopecia areata (AA) are limited. The aim of this study is to determine the association between maternal AA and risk of adverse birth outcomes in children. A retrospective cohort study was conducted on 45,328 children born to mothers with AA and 4,703,253 controls born to mothers without AA using the Korean National Health Insurance Claims database from 2002 to 2016.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!